Market openNon-fractional
Harrow Health/HROW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Harrow Health
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.
Ticker
HROW
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Nashville, United States
Employees
315
Website
www.harrow.com
Harrow Health Metrics
BasicAdvanced
$764M
Market cap
-
P/E ratio
-$0.92
EPS
0.57
Beta
-
Dividend rate
Price and volume
Market cap
$764M
Beta
0.57
Financial strength
Current ratio
3.005
Quick ratio
1.642
Long term debt to equity
305.863
Total debt to equity
305.863
Interest coverage (TTM)
-0.33%
Management effectiveness
Return on assets (TTM)
-1.79%
Return on equity (TTM)
-76.67%
Valuation
Price to revenue (TTM)
5.282
Price to book
12.84
Price to tangible book (TTM)
12.84
Price to free cash flow (TTM)
-5.043
Growth
Revenue change (TTM)
49.79%
Earnings per share change (TTM)
42.59%
3-year revenue growth
38.24%
3-year earnings per share growth
35.11%
What the Analysts think about Harrow Health
Analyst Ratings
Majority rating from 4 analysts.
Harrow Health Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$35M
-4.96%
Net income
-$14M
48.35%
Profit margin
-39.13%
56.15%
Harrow Health Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.13
-$0.25
-$0.38
-
Expected
-$0.04
$0.04
-$0.04
-$0.20
-$0.21
Surprise
250.00%
-467.93%
459.70%
90.00%
-
Harrow Health News
AllArticlesVideos
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Business Wire·4 weeks ago
Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Harrow: Merits A Buy On Sales Potential
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harrow Health stock?
Harrow Health (HROW) has a market cap of $764M as of July 05, 2024.
What is the P/E ratio for Harrow Health stock?
The price to earnings (P/E) ratio for Harrow Health (HROW) stock is 0 as of July 05, 2024.
Does Harrow Health stock pay dividends?
No, Harrow Health (HROW) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Harrow Health dividend payment date?
Harrow Health (HROW) stock does not pay dividends to its shareholders.
What is the beta indicator for Harrow Health?
Harrow Health (HROW) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Harrow Health stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.